Literature DB >> 11929703

Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies.

M Neves1, L Gano, N Pereira, M C Costa, M R Costa, M Chandia, M Rosado, R Fausto.   

Abstract

Bisphosphonates (BPs) are characterized by a P-C-P backbone structure and two phosphonic acid groups bonded to the same carbon, and are established as osteoclast-mediated bone resorption inhibitors. The nature of the groups attached to the central carbon atom are responsible in determining the potency of bisphosphonates as anti-resorption drugs. However, it is not yet clear the exact relationship between their molecular structure and pharmacologic activities. In this study, molecular geometries of pamidronate, alendronate and neridronate, differing only in the length of the aliphatic chains, were predicted by molecular mechanics and their interactions with hydroxyapatite, the main bone mineral component, were examined. We report the synthesis and radiochemical characterization of 153Sm complexes with pamidronate, alendronate and neridronate. Hydroxyapatite binding and biodistribution studies of these complexes have shown a good correlation with the theoretical molecular modeling interaction studies. So, it is possible to conclude that computational chemistry techniques are a good approach to evaluate specific interactions and may play a relevant role in determining the relative ability of BPs to mineral bone, and open new perspectives to the design of new BPs with increased pharmacological activity. These techniques could be extended to BPs as ligands to carrier radioactive metals, aiming for new bone therapeutic radiopharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929703     DOI: 10.1016/s0969-8051(01)00305-5

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  6 in total

1.  Modeling the interaction of seven bisphosphonates with the hydroxyapatite(100) face.

Authors:  Chunyu Chen; Mingzhu Xia; Lei Wu; Chao Zhou; Fengyun Wang
Journal:  J Mol Model       Date:  2012-03-27       Impact factor: 1.810

2.  Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases.

Authors:  Kazuma Ogawa; Takahiro Mukai; Keiichi Kawai; Norito Takamura; Hirofumi Hanaoka; Kazuyuki Hashimoto; Kazuhiro Shiba; Hirofumi Mori; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-16       Impact factor: 9.236

3.  SYNTHESIS OF SYMMETRICAL METHYLENEBIS(ALKYL HYDROGEN PHOSPHONATES) BY SELECTIVE CLEAVAGE OF METHYLENEBIS(DIALKYL PHOSPHONATES) WITH MORPHOLINE.

Authors:  Gantla Vidyasagar Reddy; Hollie K Jacobs; Aravamudan S Gopalan; Richard E Barrans; Mark L Dietz; Dominique C Stepinski; Albert W Herlinger
Journal:  Synth Commun       Date:  2011-10-18       Impact factor: 2.007

4.  Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer.

Authors:  Xianzhu Ke; Wen Lin; Xiaokang Li; Hailiang Wang; Xin Xiao; Zheng Guo
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

5.  Preparation, Biological Evaluation and Dosimetry Studies of 175Yb-Bis-Phosphonates for Palliative Treatment of Bone Pain.

Authors:  Ashraf Fakhari; Amir R Jalilian; Hassan Yousefnia; Saeed Shanehsazzadeh; Ali Bahrami Samani; Fariba Johari Daha; Mehdi Shafiee Ardestani; Ali Khalaj
Journal:  Mol Imaging Radionucl Ther       Date:  2015-10-05

6.  Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study.

Authors:  Massimo Varenna; Vania Braga; Davide Gatti; Giovanni Iolascon; Bruno Frediani; Francesca Zucchi; Chiara Crotti; Fabrizio Nannipieri; Maurizio Rossini
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-06-11       Impact factor: 5.346

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.